Nidan Laboratories and Healthcare Past Earnings Performance
Past criteria checks 0/6
Nidan Laboratories and Healthcare's earnings have been declining at an average annual rate of -41.2%, while the Healthcare industry saw earnings growing at 23.2% annually. Revenues have been growing at an average rate of 4% per year.
Key information
-41.2%
Earnings growth rate
-44.2%
EPS growth rate
| Healthcare Industry Growth | 29.4% |
| Revenue growth rate | 4.0% |
| Return on equity | -6.0% |
| Net Margin | -17.7% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Nidan Laboratories and Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 229 | -41 | 44 | 0 |
| 30 Jun 24 | 235 | -36 | 46 | 0 |
| 31 Mar 24 | 242 | -32 | 49 | 0 |
| 31 Dec 23 | 231 | 0 | 51 | 0 |
| 30 Sep 23 | 220 | 31 | 53 | 0 |
| 30 Jun 23 | 231 | 33 | 52 | 0 |
| 31 Mar 23 | 243 | 35 | 52 | 0 |
| 31 Dec 22 | 257 | 34 | 48 | 0 |
| 30 Sep 22 | 272 | 32 | 43 | 0 |
| 30 Jun 22 | 289 | 27 | 39 | 0 |
| 31 Mar 22 | 297 | 27 | 39 | 0 |
| 31 Mar 21 | 208 | 23 | 28 | 0 |
| 31 Mar 20 | 222 | 7 | 42 | 0 |
| 31 Mar 19 | 206 | 2 | 40 | 0 |
Quality Earnings: NIDAN is currently unprofitable.
Growing Profit Margin: NIDAN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NIDAN is unprofitable, and losses have increased over the past 5 years at a rate of 41.2% per year.
Accelerating Growth: Unable to compare NIDAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NIDAN is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (33.2%).
Return on Equity
High ROE: NIDAN has a negative Return on Equity (-6.02%), as it is currently unprofitable.